ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every corporate announcement our alert engine sent, newest first: orders, results, earnings calls, fund raises, board meetings and more.
Announcement type
Time
9,120 announcements with these filters
Q2FY27 consolidated revenue rose 25.4% YoY to ₹854 Cr. EBITDA reached ₹100 Cr at an 11.7% margin, and PAT was ₹42 Cr versus ₹15 Cr.
Q2 FY27 consolidated revenue ₹85.66 Cr (+28.5%), EBITDA ₹14.77 Cr (+53%), EBITDA margin 17.24%, PAT ₹6.82 Cr (+17.6%). Dual-engine strategy: premium nuts plus ice cream.
Q2 FY27: revenue ₹3,006 Cr (+28%), EBITDA ₹263 Cr (+65%, 8.7% margin), PAT ₹101 Cr (+207%). Growth is real, but the festive quarter is unfinished and H1 operating cash flow is negative.
Q2 FY27 consolidated revenue fell 9% to INR17,018Mn, EBITDA margin compressed to 14%, and PAT fell 70%. Domestic and Biologicals grew; agchem exports declined 18%.
Consolidated Q2 PAT rose to ₹80 Cr, but standalone PAT halved and H1 consolidated PAT fell to ₹35 Cr. H2 needs ~₹4,200 Cr revenue, a steep ramp from H1's ₹1,790 Cr standalone.
Q2 revenue grew only 3.4% YoY, while EBITDA rose 24% on pricing and cost cuts, not volume. Management kept 10% CAGR revenue guidance despite ~7% H1 growth. The 15% EBITDA margin target is framed as an aspiration.
Revenue ₹1,180 Cr, up 21% YoY, flattered by low base and GST tailwinds; underlying growth 12–13%. EBITDA margin held near 34% despite ~120 bps gross margin dilution. PAT boosted by a ₹42 Cr one-off.
Q2 FY27 pre-sales ₹2,092 Cr (~14x YoY); H1 FY27 pre-sales ₹3,184 Cr, collections ₹1,051 Cr. Reported P&L is small (FY26 revenue ₹199.4 Cr, PBT ₹23.3 Cr); ₹4,800–5,700 Cr embedded PBT to be recognised FY28–FY31.
Q2 FY27 revenue flat QoQ at ₹2,486 Mn, down 3.8% YoY; EBITDA margin 17.60%; PAT ₹321 Mn. AI-first pivot is pressuring near-term revenue.
Q2 FY27 standalone revenue ₹3,121 Mn (+52% YoY), EBITDA ₹396 Mn (12.7% margin), PAT ₹228 Mn (+77%). BTS defence/space drove growth; order book ₹19.5 Bn (+38%).
Q2FY27 revenue Rs 2,087 Cr (+32.9% reported, +34.7% LFL), EBITDA Rs 111 Cr at 5.3% margin, PAT Rs 61 Cr (+66%). Strategy: consolidate fragmented distribution and scale MedTech (IVD, cardio-ortho).
Q2 FY27 revenue ₹3,809L (+195% YoY), PAT ₹660L (17.3% margin). H1 FY27 revenue ₹7,238L, PAT ₹1,192L. Growth is acquisition-led, with Dubai entry.
H1 FY27 consolidated revenue rose about 39%, EBITDA about 40% and PAT 40%. Part of the revenue growth is metal pass-through. Management expects margins to dip as low-margin assembly scales, and its growth outlook is hedged.
Q2 FY27 consolidated revenue Rs 1,323 Cr (+28% YoY), EBITDA Rs 111 Cr (8% margin), PAT loss Rs 5 Cr. H1 PAT loss Rs 181 Cr. Speciality segments improving; commodity PVC and VAC still weak.
Q2 FY27 consolidated revenue INR 133.7 Cr, EBITDA INR 55 Cr (41% margin), PAT INR 24.8 Cr (19%). Pepperfry turnaround, Pepcart logistics, data-centre and AI platforms.
H1 FY27 revenue ₹83.46 Cr (+71.6%) and PAT ₹7.04 Cr (+126.3%) on government project execution. Margin sustainability and defence answers gave no numbers. The ₹170 Cr FY27 target is the only hard guide.
Q2 PAT ₹64.7 Cr (+54% YoY) includes a ₹15 Cr deferred tax write-back; PBT grew only 13%. Fee income (₹61.3 Cr TTM) roughly covers ₹63.4 Cr expenses, and carry is lumpy and realization-driven.
Revenue rose 18.4% but volume grew only 2.9%, so growth is mainly price-led. EBITDA margin fell about 100bps to 15.9% under input inflation, and management leans on adjusted metrics excluding PLI and Project Bold to present underlying performance.
Q2 FY27 consolidated revenue ₹16,882.76 lakh (+56.82% YoY), PAT ₹974.65 lakh (+2366% on a low base), EBITDA margin 13.98%. Strategy centres on solar, BESS and EV charging.
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Q2/H1 FY27 deck with no P&L figures in the provided slides. Strategy centres on anode expansion from 20K to 44K MT and 500 MT graphene by Sep 2028.
Q2FY27 revenue Rs 3,450 cr (+49% YoY), PAT Rs 291 cr (+10%), EBITDA margin 18.2% (-329 bps). H1 revenue Rs 6,859 cr (+35%). Targets 2.2x revenue by FY30.
Record Q2: revenue ₹359 Cr (+47%), EBITDA ₹66 Cr (+54%). No revenue guidance given. Gross margin fell 1.1 pts, and inventory of ₹358 Cr is at a seasonal peak.
Standalone Q2 PAT more than tripled to ₹10.16 Cr on ₹46.64 Cr sales. Consolidated H1 PAT of ₹18.62 Cr trails standalone ₹20.19 Cr due to Beryl subsidiary losses. Management hedges on Beryl breakeven and acquisition plans.
Q2 FY27 standalone sales ₹1,722.5 Cr (+19% YoY), EBITDA ₹191.1 Cr (11.0% margin), PAT ₹115.2 Cr (-14%). Consolidated revenue ₹2,284 Cr (+17%), PAT ₹130.3 Cr (-18%). No numerical guidance.
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Q2 revenue rose 64.4% YoY to ₹222.97 Cr and PAT 57.3% to ₹28.06 Cr, led by volume. Management deflected on equity dilution and the freeze-dried (FDC) start date, which slipped 1-2 months.
H1 revenue ₹84.06 Cr (+378% YoY from a small base), EBITDA margin 13.49%, PAT ₹8.18 Cr. Management hedged heavily ('hopefully', 'I think so') and gave no FY27 margin figure.
H1 FY27 revenue INR 839 Mn (+107% YoY), EBITDA INR 92 Mn (+19%), PAT INR 90 Mn (+27%), driven by Taggd acquisition. Margins compressed sharply.
Q2 FY27 revenue ₹584.7 Cr (+23.2%), record EBITDA margin 12.9%, PAT ₹29.0 Cr (+35.7%). H1 revenue ₹1,065.2 Cr (+30.8%). Growth led by retail and general trade.